Abstract: A power tool includes a motor, a spindle, an inner housing, an outer housing formed by an upper member and a lower member, a pair of interposing members and a pair of elastic members. The interposing members are arranged leftward and rightward of the inner housing, respectively, and fixedly connected to a first member, which is one of the upper member and the lower member, and at least partially in contact with an inner surface of the first member. The elastic members are held between a left portion of the inner housing and one of the interposing members and between a right portion of the inner housing and the other of the interposing members, respectively. A first end portion of each of the interposing members has at least one first surface extending to be closer to the inner housing toward a tip end of the first end portion.

Abstract: An information processing apparatus, a log storage method, and a non-transitory recording medium. The information processing apparatus updates firmware of a controller, updates the firmware of an operation device while the operation device is in operation, and stores a log related to the operation device in the operation device while the firmware of the controller is being updated.

Abstract: The present invention provides a vaccinia virus which specifically grows in cancer cells and damages cancer cells and use of the virus for cancer treatment. The oncolytic vaccinia is deficient in a region consisting of 7000 to 9000 nucleotides in the genome sequence of a vaccinia virus and does not grow in normal cells, but grows specifically in cancer cells and damages cancer cells specifically.

Abstract: A vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene and a therapeutic composition containing the same. The vaccinia virus contains at least one immune regulating gene as an exogenous gene.

Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

Abstract: This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: An object of the present invention is to provide an enhancer for endogenous T-cells or B-cells having a memory function and a malignant tumor recurrence inhibitor in order to continue to reject malignant tumor over a long period of time. An enhancer for T-cells or B-cells having a memory function in an administration subject, comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and an inducer for inducing a memory function in T-cells or B-cells in an administration subject, are prepared. Also, a malignant tumor recurrence inhibitor comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19, is prepared.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: A sealing device includes: an annular seal that is disposed on an outer periphery of a rod of a hydraulic cylinder further on a side of an extending direction than a cylinder head of the hydraulic cylinder and that has a pair of opposing first facing surfaces; a holding member disposed on an outer periphery of the seal; and a fixing member disposed on an outer periphery of the holding member, the fixing member having a tapered inner surface that contacts an outer surface of the holding member and that has an inner diameter increasing toward a retracting direction.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: An absorbance detector and a chromatograph with which it is possible to constantly obtain a maximum quantity of light without suppressing a drive current, even when disposed within a column oven. The disclosure includes a light-emitting unit having LED elements; a light-receiving unit having a photodiode; an absorbance detector cell comprising a cell in which a specimen is accommodated, the absorbance detector cell being disposed between the light-emitting unit and the light-receiving unit; an LED control unit for outputting a drive current to the LED elements; and a temperature sensor for detecting the surrounding temperature around the LED elements.

Abstract: A sealing device includes: an annular seal that is disposed on an outer periphery of a rod of a hydraulic cylinder further on a side of an extending direction than a cylinder head of the hydraulic cylinder and that has a pair of opposing first facing surfaces; a holding member disposed on an outer periphery of the seal; and a fixing member disposed on an outer periphery of the holding member, the fixing member having a tapered inner surface that contacts an outer surface of the holding member and that has an inner diameter increasing toward a retracting direction.

Abstract: An autosampler includes a pressure release operation unit for performing, by controlling operation of a needle drive mechanism and a switching mechanism, before a tip end of a needle is pulled out from an injection port following a state where a sampling channel is disposed between a feeding device and an analytical column, a pressure release operation of switching the switching mechanism in such a way that the sampling channel is not disposed between the feeding device and the analytical column and a system including the sampling channel is made an open system, and of performing standby until a pressure inside the sampling channel is returned to atmospheric pressure.

Abstract: The present invention has an object to provide a vaccinia virus expressing a foreign gene and capable of killing cancer cells, and a cancer therapy drug comprising the vaccinia virus. The present invention relates to a vaccinia virus, wherein a suicide gene as a foreign gene selected from the group consisting of cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, and herpes simplex virus thymidine kinase (HSV-tk) gene is introduced.

Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.

Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.

Abstract: An autosampler includes a pressure release operation unit for performing, by controlling operation of a needle drive mechanism and a switching mechanism, before a tip end of a needle is pulled out from an injection port following a state where a sampling channel is disposed between a feeding device and an analytical column, a pressure release operation of switching the switching mechanism in such a way that the sampling channel is not disposed between the feeding device and the analytical column and a system including the sampling channel is made an open system, and of performing standby until a pressure inside the sampling channel is returned to atmospheric pressure.